Coverage of "Novo Nordisk" on cryptobo.eu: the stories and the context behind them.
Novo Nordisk’s shares fell 9% after its ZEUS trial failed to hit cardiovascular endpoints, raising concerns about ziltivekimab’s development and company outlook.
